USA: In patients with advanced pulmonary arterial hypertension (PAH), adding the biologic sotatercept-csrk (Winrevair; Merck) ...

LungFit PH, Beyond Air's nitric oxide therapy device, has received the European CE mark approval for pulmonary hypertension ...

Comparison measures of lung function and improved categorization of cardiovascular disease (CVD) risk were among the key ...

Watch our fascinating panel discussion on managing pulmonary hypertension as an MDT from our Clinical Excellence in ...

Aims Pulmonary hypertension (PHT) appears to be very common in heart failure with preserved ejection fraction but details on ...

Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease ...

Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

California’s XOMA Royalty Corporation has announced that it now owns an economic interest in seralutinib, a Phase III asset being studied in pulmonary arterial hypertension (PAH), through its $20 ...

Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients ...

Royalty Corporation now owns an economic interest in seralutinib, a Phase 3 asset being studied in pulmonary arterial hypertension ...

While a check-in kiosk in healthcare settings may benefit some, it can pose challenges for older adults, columnist Colleen Steele says.